CA2825810A1 - Use of 4-aminopyridine to treat cerebral palsy - Google Patents

Use of 4-aminopyridine to treat cerebral palsy Download PDF

Info

Publication number
CA2825810A1
CA2825810A1 CA2825810A CA2825810A CA2825810A1 CA 2825810 A1 CA2825810 A1 CA 2825810A1 CA 2825810 A CA2825810 A CA 2825810A CA 2825810 A CA2825810 A CA 2825810A CA 2825810 A1 CA2825810 A1 CA 2825810A1
Authority
CA
Canada
Prior art keywords
aminopyridine
impairment
dose
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2825810A
Other languages
English (en)
French (fr)
Inventor
Thomas C. Wessel
Adrian L. Rabinowicz
Herbert R. Henney, Iii
Jacob D. Runyan
Anthony Caggiano
Andrew Blight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CA2825810A1 publication Critical patent/CA2825810A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CA2825810A 2011-01-28 2012-01-27 Use of 4-aminopyridine to treat cerebral palsy Abandoned CA2825810A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437558P 2011-01-28 2011-01-28
US61/437,558 2011-01-28
PCT/US2012/022960 WO2012103471A1 (en) 2011-01-28 2012-01-27 Use of potassium channel blockers to treat cerebral palsy

Publications (1)

Publication Number Publication Date
CA2825810A1 true CA2825810A1 (en) 2012-08-02

Family

ID=45567148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2825810A Abandoned CA2825810A1 (en) 2011-01-28 2012-01-27 Use of 4-aminopyridine to treat cerebral palsy

Country Status (7)

Country Link
US (1) US20130030025A1 (enExample)
EP (2) EP2995305B1 (enExample)
JP (3) JP2014503596A (enExample)
AU (1) AU2012211101B2 (enExample)
BR (1) BR112013019265A2 (enExample)
CA (1) CA2825810A1 (enExample)
WO (1) WO2012103471A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
HK1221666A1 (zh) * 2013-04-15 2017-06-09 Acorda Therapeutics, Inc. 氨基吡啶用於治疗与某些中风类型相关的视觉障碍的方法
WO2017168333A1 (en) * 2016-04-02 2017-10-05 Shilpa Medicare Limited Amifampridine dihydrochloride
US11730769B2 (en) * 2017-12-22 2023-08-22 Children's Medical Center Corporation Compositions and methods for Williams Syndrome (WS) therapy
US20220096609A1 (en) * 2019-02-06 2022-03-31 Allergan, Inc. Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent
CA3176457A1 (en) * 2020-04-08 2021-10-14 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury
KR20230015433A (ko) * 2020-05-22 2023-01-31 인트라바이오 리미티드 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008036294A2 (en) * 2006-09-19 2008-03-27 Northwestern University Nos inhibitors for treatment of motor deficit disorders
EP2167107B1 (en) * 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
PE20120791A1 (es) * 2009-02-11 2012-07-08 Acorda Therapeutics Inc Composiciones y metodos para terapia prolongada con aminopiridinas
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي

Also Published As

Publication number Publication date
US20130030025A1 (en) 2013-01-31
AU2012211101B2 (en) 2017-04-20
EP2995305A1 (en) 2016-03-16
JP2014503596A (ja) 2014-02-13
AU2012211101A1 (en) 2013-08-15
JP2016222685A (ja) 2016-12-28
EP2667869A1 (en) 2013-12-04
BR112013019265A2 (pt) 2016-10-11
WO2012103471A1 (en) 2012-08-02
JP2018197242A (ja) 2018-12-13
EP2995305B1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
AU2012211101B2 (en) Use of potassium channel blockers to treat cerebral palsy
AU2018200114A1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
US20200230121A1 (en) Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
Sullivan et al. Levetiracetam for the treatment of generalized dystonia
NZ713140B2 (en) Use of potassium channel blockers to treat cerebral palsy
NZ713140A (en) Use of potassium channel blockers to treat cerebral palsy
US20160058743A1 (en) Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
Iaccarino et al. Management of Brain Injury Related Spasticity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180126

FZDE Discontinued

Effective date: 20211005

FZDE Discontinued

Effective date: 20211005

FZDE Discontinued

Effective date: 20211005